Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva

Development of innovative therapies in intensive care medicine is particularly important since diseases as sepsis, acute respiratory distress syndrome (ARDS) and acute renal injury (AKI) have an elevated morbidity and mortality in spite of current gold-standard approaches. Mesenchymal stem cells (MS...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Espinoza,Francisco, Aliaga,Felipe, Crawford,Patricia Luz
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2016
Materias:	Acute Kidney Injury Mesenchymal stromal cells Respiratory Distress Syndrome Adult Sepsis
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200011
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872016000200011
record_format	dspace
spelling	oai:scielo:S0034-988720160002000112016-04-13Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensivaEspinoza,FranciscoAliaga,FelipeCrawford,Patricia Luz Acute Kidney Injury Mesenchymal stromal cells Respiratory Distress Syndrome Adult Sepsis Development of innovative therapies in intensive care medicine is particularly important since diseases as sepsis, acute respiratory distress syndrome (ARDS) and acute renal injury (AKI) have an elevated morbidity and mortality in spite of current gold-standard approaches. Mesenchymal stem cells (MSC) may have a promising role due to their properties in immunomodulation, tissue reparation and microbial clearance. Preclinical data and results of a systematic review of PubMed, PMC and ClinicalTrials.gov have been included to review the role of MSC therapy in sepsis, ARDS and AKI. A description of MSC biology, sources and benefits in preclinical models was included. A phase I/II clinical trial (RCT) is recruiting neutropenic patients with septic shock. In ARDS, the START trial (Stem cells in ARDS Treatment) is a phase I/II study of bone marrow-derived human MSC (hMSC) that is currently recruiting patients. In AKI, a phase I study has demonstrated the safety of hMSCs infusion in patients undergoing cardiac surgery with high risk to develop AKI. A phase II study is still active. The results of these studies will determine the real feasibility of MSC therapy in critically ill patients.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.144 n.2 20162016-02-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200011es10.4067/S0034-98872016000200011
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Acute Kidney Injury Mesenchymal stromal cells Respiratory Distress Syndrome Adult Sepsis
spellingShingle	Acute Kidney Injury Mesenchymal stromal cells Respiratory Distress Syndrome Adult Sepsis Espinoza,Francisco Aliaga,Felipe Crawford,Patricia Luz Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
description	Development of innovative therapies in intensive care medicine is particularly important since diseases as sepsis, acute respiratory distress syndrome (ARDS) and acute renal injury (AKI) have an elevated morbidity and mortality in spite of current gold-standard approaches. Mesenchymal stem cells (MSC) may have a promising role due to their properties in immunomodulation, tissue reparation and microbial clearance. Preclinical data and results of a systematic review of PubMed, PMC and ClinicalTrials.gov have been included to review the role of MSC therapy in sepsis, ARDS and AKI. A description of MSC biology, sources and benefits in preclinical models was included. A phase I/II clinical trial (RCT) is recruiting neutropenic patients with septic shock. In ARDS, the START trial (Stem cells in ARDS Treatment) is a phase I/II study of bone marrow-derived human MSC (hMSC) that is currently recruiting patients. In AKI, a phase I study has demonstrated the safety of hMSCs infusion in patients undergoing cardiac surgery with high risk to develop AKI. A phase II study is still active. The results of these studies will determine the real feasibility of MSC therapy in critically ill patients.
author	Espinoza,Francisco Aliaga,Felipe Crawford,Patricia Luz
author_facet	Espinoza,Francisco Aliaga,Felipe Crawford,Patricia Luz
author_sort	Espinoza,Francisco
title	Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
title_short	Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
title_full	Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
title_fullStr	Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
title_full_unstemmed	Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
title_sort	escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva
publisher	Sociedad Médica de Santiago
publishDate	2016
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872016000200011
work_keys_str_mv	AT espinozafrancisco escenarioactualyperspectivasdelaterapiaconcelulasmadremesenquimalesenmedicinaintensiva AT aliagafelipe escenarioactualyperspectivasdelaterapiaconcelulasmadremesenquimalesenmedicinaintensiva AT crawfordpatricialuz escenarioactualyperspectivasdelaterapiaconcelulasmadremesenquimalesenmedicinaintensiva
_version_	1718436866654470144

Escenario actual y perspectivas de la terapia con células madre mesenquimales en medicina intensiva

Ejemplares similares